Ascentage Pharma Group International (NASDAQ:AAPG) Stock Rated Market Outperform in New Coverage at Citizens Jmp

Equities researchers at Citizens Jmp began coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage set a “market outperform” rating and a $35.00 price target on the stock. Citizens Jmp’s price target would indicate a potential upside of 127.64% from the company’s previous close.

Several other brokerages have also recently commented on AAPG. Citigroup assumed coverage on shares of Ascentage Pharma Group International in a research report on Tuesday. They set an “outperform” rating on the stock. BTIG Research reissued a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, JPMorgan Chase & Co. cut their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. Two research analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $43.67.

Ascentage Pharma Group International Stock Up 4.2%

AAPG opened at $15.38 on Tuesday. The firm’s fifty day moving average price is $16.68 and its 200 day moving average price is $19.27. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. Ascentage Pharma Group International has a 12-month low of $14.45 and a 12-month high of $37.50.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The business had revenue of $22.24 million for the quarter. On average, equities research analysts anticipate that Ascentage Pharma Group International will post -2.42 earnings per share for the current fiscal year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.